ONKT 104
Alternative Names: ONKT-104Latest Information Update: 15 Sep 2021
At a glance
- Originator ONK Therapeutics
- Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Acute myeloid leukaemia
Most Recent Events
- 09 Sep 2021 ONK Therapeutics has patent protection for CISH knockout in NK cells for use in cancer therapies in the US
- 09 Sep 2021 ONK Therapeutics has patents pending for CISH KO in NK cells in the US, the EU, China, Japan, Australia and New Zealand
- 27 May 2021 ONK Therapeutics in-licenses patented CISH KO NK cells from Walter and Eliza Hall Institute of Medical Research (WEHI)